Long-term mortality and patency after drug-coated balloon angioplasty in the hemodialysis circuit: A systematic review and meta-analysis of randomized controlled trials

Abstract

Purpose:

To compare all-cause mortality and primary patency with drug-coated balloon angioplasty (DCBA) compared with plain balloon angioplasty (PBA) in people with hemodialysis-related stenosis.

Materials and methods:

PubMed, Embase, and Cochrane Library databases were searched from November 1966 to February 2021 to identify randomized controlled trials (RCTs) that assessed the use of DCBA versus PBA for stenosis in hemodialysis circuits. Data extracted from the articles were integrated to determine all-cause mortality, target lesion primary patency (TLPP), circuit access primary patency (CAPP), 30-day adverse events, and technical success for the two approaches. We performed meta-analysis on these results using a fixed-effects model to evaluate odds ratios (ORs) and 95% confidence intervals (CIs) where I² < 50% in a test for heterogeneity, or a random-effect model if otherwise. Sensitivity and subgroup analyses were also performed.

Results:

Sixteen RCTs of 1672 individuals were included in our meta-analysis, of which 839 individuals received DCBA and 833 received PBA. The pooled outcome showed no statistical difference between DCBA and PBA in all-cause mortality at 6 months (OR = 1.29, 95% CI = 0.72–2.32, p = 0.39, I² = 4%), 12 months (OR = 1.02, 95% CI = 0.68–1.53, p = 0.91, I² = 0%), and 24 months (OR = 1.50, 95% CI = 0.87–2.57, p = 0.15, I² = 0%), 30-day adverse events (OR = 1.09, 95% CI = 0.30–3.98, p = 0.90, I² = 66%), and technical success (OR = 0.18, 95% CI = 0.02–1.92, p = 0.16, I² = 65%). The DCBA had significantly better outcomes versus PBA in TLPP at 6 months (OR = 2.37, 95% CI = 1.84–3.04, p < 0.001, I² = 44%) and 12 months (OR = 1.77, 95% CI = 1.22–2.56, p = 0.002, I² = 56%), and CAPP at 6 months (OR = 2.07, 95% CI = 1.21–3.54, p = 0.008, I² = 67%) and 12 months (OR = 1.66, 95% CI = 1.29–2.15, p < 0.001, I² = 0%).

Conclusion:

In hemodialysis circuit stenosis, DCBA appears to have similar safety but greater efficacy than PBA.

Keywords

Hemodialysis circuit balloon angioplasty drug-coated balloon mortality primary patency stenosis

Get full access to this article

View all access options for this article.

References

Saran

Robinson

Abbott

. United States Renal data System: 2016 USRDS annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis 2017; 69(3): A4.

Chatzimanouil

MKT

Wilkens

Anders

. Quantity and reporting quality of kidney research. J Am Soc Nephrol 2019; 30(1): 13–22.

Lok

Huber

Lee

, et al. KDOQI clinical practice guideline for vascular access: 2019 update. Am J Kidney Dis 2020; 75(4): S1–S164.

Viecelli

Mori

Roy-Chaudhury

, et al. The pathogenesis of hemodialysis vascular access failure and systemic therapies for its prevention: optimism unfulfilled. Semin Dial 2018; 31(3): 244–257.

Riella

Roy-Chaudhury

. Vascular access in haemodialysis: strengthening the Achilles’ heel. Nat Rev Nephrol 2013; 9(6): 348–357.

Roy-Chaudhury

Wang

Krishnamoorthy

, et al. Cellular phenotypes in human stenotic lesions from haemodialysis vascular access. Nephrol Dial Transplant 2009; 24(9): 2786–2791.

Kennedy

Mafeld

Baerlocher

, et al. Drug-Coated balloon angioplasty in hemodialysis circuits: a systematic review and meta-analysis. J Vasc Interv Radiol 2019; 30(4): 483–494.e1.

Cao

Zhang

, et al. Comparative effectiveness of drug-coated balloon vs balloon angioplasty for the treatment of arteriovenous fistula stenosis: a meta-analysis. J Endovasc Ther 2020; 27(2): 266–275.

Tripsianis

Christaina

Argyriou

, et al. Network meta-analysis of trials comparing first line endovascular treatments for arteriovenous fistula stenosis. J Vasc Surg 2021; 73: 2198–2203.e3.

10.

Chen

Liu

Wang

, et al. A systematic review and meta-analysis of the risk of death and patency after application of paclitaxel-coated balloons in the hemodialysis access. J Vasc Surg 2020; 72(6): 2186–2196.e3.

11.

Rokoszak

Syed

Salata

, et al. A systematic review and meta-analysis of plain versus drug-eluting balloon angioplasty in the treatment of juxta-anastomotic hemodialysis arteriovenous fistula stenosis. J Vasc Surg 2020; 71(3): 1046–1054.e1.

12.

Schmidt

Piorkowski

Görner

, et al. Drug-coated balloons for complex femoropopliteal lesions: 2-year results of a real-world registry. JACC Cardiovasc Interv 2016; 9(7): 715–724.

13.

Tepe

Zeller

Albrecht

, et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. New Engl J Med 2008; 358(7): 689–699.

14.

Lookstein

Haruguchi

Ouriel

, et al. Drug-coated balloons for dysfunctional dialysis arteriovenous fistulas. New Engl J Med 2020; 383(8): 733–742.

15.

Trerotola

Lawson

Roy-Chaudhury

, et al. Drug coated balloon angioplasty in failing AV fistulas: a randomized controlled trial. Clin J Am Soc Nephrol 2018; 13(8): 1215–1224.

16.

Yin

Shi

Cui

, et al. Efficacy and safety of paclitaxel-coated balloon angioplasty for dysfunctional arteriovenous fistulas: a multicenter randomized controlled trial. Am J Kidney Dis 2021; 78: 19–27.e1.

17.

Liao

Lee

Lin

, et al. A randomized controlled trial of drug-coated balloon angioplasty in venous anastomotic stenosis of dialysis arteriovenous grafts. J Vasc Surg 2020; 71(6): 1994–2003.

18.

Björkman

Weselius

Kokkonen

, et al. Drug-Coated versus plain balloon angioplasty In arteriovenous fistulas: a randomized, controlled study with 1-year follow-Up (the Drecorest Ii-study). Scand J Surg 2019; 108(1): 61–66.

19.

Katsanos

Spiliopoulos

Kitrou

, et al. Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc 2018; 7(24): e011245.

20.

Gray

Sacks

Martin

, et al. Reporting standards for percutaneous interventions in dialysis access. J Vasc Interv Radiol 2003; 14(9): S433–S442.

21.

Katsanos

Karnabatidis

Kitrou

, et al. Paclitaxel-coated balloon angioplasty vs. plain balloon dilation for the treatment of failing dialysis access: 6-month interim results from a prospective randomized controlled trial. J Endovasc Ther 2012; 19(2): 263–272.

22.

Kitrou

Katsanos

Spiliopoulos

, et al. Drug-eluting versus plain balloon angioplasty for the treatment of failing dialysis access: final results and cost-effectiveness analysis from a prospective randomized controlled trial (NCT01174472). Eur J Radiol 2015; 84(3): 418–423.

23.

Kitrou

Spiliopoulos

Katsanos

, et al. Paclitaxel-coated versus plain balloon angioplasty for dysfunctional arteriovenous fistulae: one-year results of a prospective randomized controlled trial. J Vasc Interv Radiol 2015; 26(3): 348–354.

24.

Kitrou

Papadimatos

Spiliopoulos

, et al. Paclitaxel-Coated balloons for the treatment of symptomatic central venous stenosis in dialysis access: results from a randomized controlled trial. J Vasc Interv Radiol 2017; 28(6): 811–817.

25.

Irani

Teo

TKB

Tay

, et al. Hemodialysis arteriovenous fistula and graft stenoses: randomized trial comparing drug-eluting balloon angioplasty with conventional angioplasty. Radiology 2018; 289(1): 238–247.

26.

Maleux

Vander Mijnsbrugge

Henroteaux

, et al. Multicenter, randomized trial of conventional balloon angioplasty versus paclitaxel-coated balloon angioplasty for the treatment of dysfunctioning autologous dialysis fistulae. J Vasc Interv Radiol 2018; 29(4): 470–475.e3.

27.

Swinnen

J“

Hitos

Kairaitis

, et al. Multicentre, randomised, blinded, control trial of drug-eluting balloon vs sham in recurrent native dialysis fistula stenoses. J Vasc Access 2019; 20(3): 260–269.

28.

Moreno-Sánchez

Moreno-Ramírez

Machancoses

, et al. Efficacy of Paclitaxel balloon for hemodialysis stenosis fistulae after One Year compared to high-pressure balloons: a controlled, multicenter, randomized trial. Cardiovasc Intervent Radiol 2020; 43(3): 382–390.

29.

Kim

Byun

, et al. Paclitaxel-Coated balloon versus plain balloon angioplasty for dysfunctional autogenous radiocephalic arteriovenous fistulas: a prospective randomized controlled trial. Korean J Radiol 2020; 21(11): 1239–1247.

30.

Pang

SYC

Au-Yeung

KCL

Liu

GYL

, et al. Randomized controlled trial for paclitaxel-coated balloon versus plain balloon angioplasty in dysfunctional hemodialysis vascular access: 12-month outcome from a nonsponsored trial. Ann Vasc Surg 2021; 72: 299–306.

31.

Therasse

Caty

Gilbert

, et al. Safety and efficacy of paclitaxel-eluting balloon angioplasty for dysfunctional hemodialysis access: a randomized trial comparing with angioplasty alone. J Vasc Interv Radiol 2021; 32: 350–359.e2.

32.

Trerotola

Saad

Roy-Chaudhury

. The Lutonix AV randomized trial of paclitaxel-coated balloons in arteriovenous fistula stenosis: 2-year results and subgroup analysis. J Vasc Interv Radiol 2020; 31(1): 1–14.e5.

33.

Albalas

Almehmi

. Arterial emboli in the setting of prolonged dialysis access thrombosis. J Am Soc Nephrol 2020; 31: 445–446.

34.

Cheung

Imrey

Alpers

, et al. Intimal hyperplasia, stenosis, and arteriovenous fistula maturation failure in the hemodialysis fistula maturation study. J Am Soc Nephrol 2017; 28(10): 3005–3013.

35.

Khawaja

Cassidy

Shakarchi

, et al. Drug eluting balloon angioplasty for arteriovenous haemodialysis access stenosis: a systematic review and meta-analysis. J Vasc Access 2016; 17(2): 103–110.

36.

Yazar

Provoost

Broughton

, et al. Paclitaxel drug-coated balloon angioplasty for the treatment of failing arteriovenous fistulas: a single-center experience. Acta Chir Belg 2020; 120(2): 85–91.

37.

Somma

Ferro

Paudice

, et al. Drug coated balloons reduce the risk of restenosis in hemodialysis patients with recurrent stenosis of arteriovenous fistula. Nephrol Dial Transplant 2017; 32: 668–669.

38.

Troisi

Frosini

Somma

, et al. Drug-coated balloons reduce the risk of recurrent restenosis in arteriovenous fistulas and prosthetic grafts for hemodialysis. Int Angiol 2018; 37(1): 59–63.

39.

Collins

Foley

Herzog

, et al. Excerpts from the US renal data system 2009 annual data report. Am J Kidney Dis 2010; 55(1): A6–A7.

40.

Bloembergen

Port

Mauger

, et al. Causes of death in dialysis patients: racial and gender differences. J Am Soc Nephrol 1994; 5(5): 1231–1242.

41.

Cohen

McCue

Germain

, et al. Dialysis discontinuation: a ‘good’ death? Arch Intern Med 1995; 155(1): 42–47.

42.

Wallen

Radhakrishnan

Appel

, et al. An analysis of cardiac mortality in patients with new-onset end-stage renal disease in New York state. Clin Nephrol 2001; 55(2): 101–108.

43.

Wall

. Camptothecin and taxl. In: Chronicles of drug discovery. 1993, pp.327–348.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.21 MB